ABSTRACT
Bio-based aerogel (polysaccharide cryogel) have led to a growing interest because of eco-friendliness, sustainability and excellent thermal insulation properties. Herein, we report an eco-friendly strategy to construct lightweight and porous sodium alginate/carboxymethyl cellulose/chitosan polysaccharide-based composite aerogels (SCC-B) by freeze-drying and post-cross-linking technology. The ester cross-linking of polysaccharide component achieved strong web-like entangled structure when using 1,2,3,4-butanetetracarboxylic acid and sodium hypophosphite as eco-friendly co-additives, meanwhile significantly improved flame retardancy of SCC-B due to phosphorylation. The thermal kinetic behavior of SCC-B was investigated by Flynn-Wall-Ozawa and Kissinger models. Results indicated that peak heat release rate and total heat release of SCC-B decreased from 30 W/g to 20 W/g and 15 kJ/g to 10 kJ/g, respectively. Furthermore, the second-degree burn time of SCC-B reached up to 87.1 s under heat exposure of 11.3 kW/m2. These characteristics combine to suggest hopeful prospects for use of SCC-B in the fields of fire-protection clothing as a renewable flame-retardant material.
Subject(s)
Alginates/chemistry , Carboxymethylcellulose Sodium/chemistry , Chitosan/chemistry , Cryogels/chemistry , Flame Retardants , Alginates/chemical synthesis , Alginates/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Carboxymethylcellulose Sodium/chemical synthesis , Carboxymethylcellulose Sodium/pharmacology , Chitosan/chemical synthesis , Chitosan/pharmacology , Compressive Strength , Cryogels/chemical synthesis , Cryogels/pharmacology , Escherichia coli/drug effects , Flame Retardants/chemical synthesis , Flame Retardants/pharmacology , Kinetics , Materials Testing , Microbial Sensitivity Tests , Porosity , Staphylococcus aureus/drug effects , Thermal ConductivityABSTRACT
BACKGROUND: Ulcerative colitis (UC) is a modern refractory disease, and its etiology has been difficult to discern. Studies have shown that UC is closely associated with the gut microbiota. Garidisan is composed of wild poppy and Artemisia frigida Willd and is commonly used for the treatment of UC in Inner Mongolia, China. In clinical settings, Garidisan has been found to treat UC effectively, with low recurrence. Previous studies have shown that Garidisan has a good therapeutic effect on mice with UC, but the therapeutic mechanism is still unclear. In this study, we investigated the regulatory effect of Garidisan on dysbiosis of the gut microbiota in a UC mouse model and explored the possible mechanism of the therapeutic effect of Garidisan on UC. METHODS: The UC mouse model was established by the dextran sulfate sodium (DSS) circulating free water drinking method, and the luminal contents were sampled under sterile conditions. High-throughput sequencing of the 16S rRNA gene V3 + V4 region of the luminal contents of the control group, model group, and Garidisan group was conducted, and clustering of operational taxonomic units (OTUs) and species annotation were performed. The differences in species composition and microbial community structure between individual groups of samples were analyzed using MetaStat, LefSe, rank sum test, and Bayesian causal network analysis. RESULTS: The UC mouse model was successfully established and the sequencing results were of adequate quality. There were significant differences in the diversity of luminal contents between the control group, model group, and Garidisan group, and the differences between groups were greater than those within any group. The therapeutic effect of Garidisan on UC is attributed to the direct effect on the Lachnospiraceae family of bacteria. CONCLUSION: Garidisan has a good regulatory effect on the gut microbiota, and Lachnospiraceae could be an important direct target of Garidisan for the treatment of UC.
Subject(s)
Colitis, Ulcerative/microbiology , Dysbiosis/microbiology , Gastrointestinal Microbiome/drug effects , Plant Extracts/pharmacology , Animals , Bacteria/classification , Bacteria/genetics , Dextran Sulfate , Disease Models, Animal , Male , Medicine, East Asian Traditional , Mice , Mice, Inbred C57BLABSTRACT
BACKGROUND: Recent studies have found gut microbiota to be closely associated with onset and perpetuation of UC. Currently, studies about gut microbiota have mainly covered samples collected from the intestinal lumen. However, the luminal flora is only part of the gut microbiota. Studies of the changes in mucosal flora under pathological conditions have been lacking. In this study, we investigated the correlation between the onset of UC and flora changes in different intestinal layers. METHODS: The dextran sulfate sodium(DSS)-induced UC model was established by exposing mice to cycles of DSS. The luminal contents, an inner mucus layer, and outer mucus layer were harvested under sterile conditions. The samples were then analyzed using high-throughput sequencing of 16S rRNA V3 + V4 amplicons. The colonic microbiota composition and diversity were analyzed and compared using MetaStat, LefSe, multivariate analysis of variance, and spatial statistics. RESULTS: The DSS-induced UC mouse model was successfully established. The diversity of the microbiota from luminal content, the outer mucus layer, and inner mucus layer were significantly different in both control and UC model groups. The statistically different OTUs belonged to Lachnospiraceae and Ruminococcaceae families within the order Clostridiales were mainly localized to the outer mucus layer. CONCLUSIONS: The alterations in flora composition and diversity mainly occurred in the colonic outer mucus layer. The change of flora in the colonic mucus layers is of great significance in the understanding of common features of gut flora in IBD and the understanding of the relationship between gut flora and disease progression.
Subject(s)
Colitis, Ulcerative/microbiology , Colon/microbiology , Gastrointestinal Microbiome/physiology , Intestinal Mucosa/microbiology , Animals , Disease Models, Animal , Disease Progression , Gastrointestinal Microbiome/genetics , High-Throughput Nucleotide Sequencing , Male , Mice, Inbred BALB C , RNA, Ribosomal, 16S/geneticsABSTRACT
Garidisan, commonly used in Mongolia to treat ulcerative colitis (UC), contains wild poppy and Artemisia frigida Willd. Clinical evidence shows that Garidisan can effectively treat UC and that recurrence is low. Thus, we evaluated the effects of Garidisan on ulcer healing quality and the regulation of immune balance in rats with experimental UC. UC was induced by immunization with TNBS and Garidisan significantly reduced DAI, CMDI, and HS. H&E staining, SEM, and VG staining showed that Garidisan repaired damaged intestinal mucosa and significantly reduced expression of ICAM-1 and CD105 in regenerated tissues of UC rats. Collagen fibers were significantly fewer as well after treatment. Garidisan elevated EGF, VEGF, bFGF, VEGFR2, and FGFR1 of UC rats, reduced CD3+CD4+/CD3+CD8+ T cell ratios, and increased CD4+Th1/CD4+Th2 cell ratios and IFN-r/IL-4 ratios in peripheral blood of UC rats. In conclusion, Garidisan promoted tissue maturation of regenerated tissues by regulating the immune balance and improved functional maturity of regenerated tissues by reducing collagen formation, promoting maturation of new blood vessels, and increasing expression of growth factors and their receptors.
